Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome

被引:25
|
作者
Ge, Mengyuan [1 ,2 ]
Molina, Judith [1 ,2 ]
Kim, Jin-Ju [1 ,2 ]
Mallela, Shamroop K. [1 ,2 ]
Ahmad, Anis [3 ]
Varona Santos, Javier [1 ,2 ]
Al-Ali, Hassan [1 ,2 ]
Mitrofanova, Alla [1 ,2 ]
Sharma, Kumar [4 ]
Fontanesi, Flavia [5 ]
Merscher, Sandra [1 ,2 ]
Fornoni, Alessia [1 ,2 ]
机构
[1] Univ Miami, Dept Med, Miller Sch Med, Katz Family Div Nephrol & Hypertens, Miami, FL 33136 USA
[2] Univ Miami, Peggy & Harold Katz Family Drug Discovery Ctr, Miller Sch Med, Miami, FL 33136 USA
[3] Univ Miami, Dept Radiat Oncol, Miller Sch Med, Miami, FL USA
[4] Univ Texas Hlth San Antonio, Ctr Precis Med, Sch Med, San Antonio, TX USA
[5] Univ Miami, Dept Biochem & Mol Biol, Miami, FL USA
来源
ELIFE | 2023年 / 12卷
基金
美国国家卫生研究院;
关键词
Alport syndrome; lipid; energy substrate; SGLT2; inhibitor; Mouse; COTRANSPORTER; 2; INHIBITION; FATTY-ACID OXIDATION; DIABETIC KIDNEY; CELL-LINES; SGLT2; METABOLISM; EXPRESSION; MUTATIONS; APOPTOSIS; DISEASE;
D O I
10.7554/eLife.83353
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are anti-hyperglycemic agents that prevent glucose reabsorption in proximal tubular cells. SGLT2i improves renal outcomes in both diabetic and non-diabetic patients, indicating it may have beneficial effects beyond glycemic control. Here, we demonstrate that SGLT2i affects energy metabolism and podocyte lipotoxicity in experimental Alport syndrome (AS). In vitro, we found that the SGLT2 protein was expressed in human and mouse podocytes to a similar extent in tubular cells. Newly established immortalized podocytes from Col4a3 knockout mice (AS podocytes) accumulate lipid droplets along with increased apoptosis when compared to wild-type podocytes. Treatment with SGLT2i empagliflozin reduces lipid droplet accumulation and apoptosis in AS podocytes. Empagliflozin inhibits the utilization of glucose/pyruvate as a metabolic substrate in AS podocytes but not in AS tubular cells. In vivo, we demonstrate that empagliflozin reduces albuminuria and prolongs the survival of AS mice. Empagliflozin-treated AS mice show decreased serum blood urea nitrogen and creatinine levels in association with reduced triglyceride and cholesterol ester content in kidney cortices when compared to AS mice. Lipid accumulation in kidney cortices correlates with a decline in renal function. In summary, empagliflozin reduces podocyte lipotoxicity and improves kidney function in experimental AS in association with the energy substrates switch from glucose to fatty acids in podocytes.
引用
收藏
页数:22
相关论文
共 50 条
  • [21] Metformin ameliorates the severity of experimental Alport syndrome
    Kohei Omachi
    Shota Kaseda
    Tsubasa Yokota
    Misato Kamura
    Keisuke Teramoto
    Jun Kuwazuru
    Haruka Kojima
    Hirofumi Nohara
    Kosuke Koyama
    Sumio Ohtsuki
    Shogo Misumi
    Toru Takeo
    Naomi Nakagata
    Jian-Dong Li
    Tsuyoshi Shuto
    Mary Ann Suico
    Jeffrey H. Miner
    Hirofumi Kai
    Scientific Reports, 11
  • [22] Cell cycle regulatory proteins in podocyte cell in Alport syndrome (AS) and congenital nephrotic syndrome of the Finnish type (CNF)
    Srivastava, T
    Garola, RE
    Whiting, JM
    Alon, US
    PEDIATRIC RESEARCH, 2003, 53 (04) : 523A - 523A
  • [23] Comprehensive Characterization of Podocyte Lipotoxicity to Elucidate New Mechanisms for Podocyte-Protective Strategies
    Sewerin, Sebastian
    Boone, Dylan
    Ross, Lindsey
    Kim, Choah
    Pablo, Juan Lorenzo B.
    Greka, Anna
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [24] The Accumulation of VEGFA in the Glomerular Basement Membrane and Its Relationship with Podocyte Injury and Proteinuria in Alport Syndrome
    Wang, Haiyan
    Yue, Zhihui
    Wu, Jinlang
    Liu, Ting
    Mo, Ying
    Jiang, Xiaoyun
    Sun, Liangzhong
    PLOS ONE, 2015, 10 (08):
  • [25] Alport Syndrome With Kidney Cysts Is Still Alport Syndrome
    Savige, Judy
    Mack, Heather
    Thomas, Rose
    Langsford, David
    Pianta, Tim
    KIDNEY INTERNATIONAL REPORTS, 2022, 7 (02): : 339 - 342
  • [26] ALPORT SYNDROME
    MIRRA, JM
    MAYO CLINIC PROCEEDINGS, 1982, 57 (05) : 329 - 330
  • [27] Alport syndrome
    Brazzi, Luca
    Sales, Gabriele
    Montrucchio, Giorgia
    Costamagna, Andrea
    Rosado Rubio, Consolacion
    Dominguez-Garrido, Elena
    ANASTHESIOLOGIE & INTENSIVMEDIZIN, 2019, 60 : S405 - S414
  • [28] ALPORT SYNDROME
    LOPEZCAM.JL
    LOPEZSAN.A
    DELGADOY.JC
    MONTAGUT, R
    PEREZCRE.J
    PEREZGUZ.E
    PATOLOGIA-MADRID, 1974, 7 (03): : 207 - 224
  • [29] Alport syndrome
    Kashtan, CE
    Michael, AF
    KIDNEY INTERNATIONAL, 1996, 50 (05) : 1445 - 1463
  • [30] Alport syndrome
    Karki, P.
    Shrestha, J. K.
    NEPALESE JOURNAL OF OPHTHALMOLOGY, 2009, 1 (02) : 139 - 140